CN101500556A - Compositions containing zinc salts for coating medical articles - Google Patents

Compositions containing zinc salts for coating medical articles Download PDF

Info

Publication number
CN101500556A
CN101500556A CNA2006800554966A CN200680055496A CN101500556A CN 101500556 A CN101500556 A CN 101500556A CN A2006800554966 A CNA2006800554966 A CN A2006800554966A CN 200680055496 A CN200680055496 A CN 200680055496A CN 101500556 A CN101500556 A CN 101500556A
Authority
CN
China
Prior art keywords
weight
goods
concentration
acid
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800554966A
Other languages
Chinese (zh)
Inventor
S·M·莫达克
L·卡拉斯
C·麦克西瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vsp Technology Ltd By Share Ltd
Columbia University in the City of New York
Original Assignee
Vsp Technology Ltd By Share Ltd
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vsp Technology Ltd By Share Ltd, Columbia University in the City of New York filed Critical Vsp Technology Ltd By Share Ltd
Priority to CNA2006800554966A priority Critical patent/CN101500556A/en
Publication of CN101500556A publication Critical patent/CN101500556A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts and antimicrobial agents in coatings for medical articles. The coatings have an anti-irritant effect and inhibit transmission of infectious disease.

Description

The compositions that contains zinc salt that is used for coating medical articles
1. introduce
The present invention relates in the coating of goods (for example medical article), use the method and composition of the combination of low concentration zinc salt and antimicrobial.This coating has the irritation effect and can prevent the spread of infectious diseases.
2. background of invention
Center for Disease Control (CDC) (CDC) estimates that hospital acquired infections will spend 4,500,000,000 dollars of U.S. sanitary health care systems every year, and 80% infection is by direct contact infection.Found that the hot oxygen glycerol of emollient solvent (＂ Sensiva ＂) has antimicrobial acivity, especially in the presence of quaternary ammonium compound and extra antimicrobial (being the activating agent that adopts in the hand disinfection agent prescription) (referring to United States Patent (USP) 6,846,846).Except antimicrobial topical preparation or as its alternative form, health care worker and the mode of in such as other department of food service industry, using the glove conduct to protect from infection and propagate.Yet many people suffer from or develop into the glove sensitivity, comprise anaphylaxis or the dermatosis reaction to preserving moisture to latex.
Have recognized that zinc salt can suppress the stimulation that many reagent cause.For example referring to, United States Patent (USP) 5,708,023,5,965,610,6,037,386 and 5,985,918.These patent disclosures use the zinc of higher concentration, for oral administration may being harmful under this concentration.
3. summary of the invention
The present invention relates to be coated with goods, the especially medical article of the combination of two or more water-soluble zinc salts and one or more antimicrobials.Described coating also can comprise such as emollient solvent, quintessence oil or reagent such as its component and/or silicone powder.The goods that can apply according to the present invention include but not limited to: glove, men's and condom for female, curative activity clothes, binder, footware etc.Coating of the present invention can improve the protective value of goods, reduces the skin irritation that contacts generation with goods simultaneously.
4. detailed Description Of The Invention
The present invention relates to the method and composition that is used for coated article (especially medical article) at least in part, under the situation of barrier medical article and the medical article that contacts with skin or mucosa, improve the barrier effectiveness that prevents infectious disease transmission and reduce skin and/or the mucous membrane irritation that goods cause respectively.
In each embodiment, the invention provides low concentration water-soluble zinc salt and one or more antimicrobials with the coating of the goods of contact skin in application.Described goods include but not limited to; barrier articles, for example glove, condom, barrier film and such as the goods of eye protector, the medical door curtain made of cloth, protective garment, footware, wound dressing, the device (for example colostomy bag, tracheostomy tube and accessory) that is applied to fistula mouth (stoma), surgical face mask etc.The example of the non-medical article that can apply according to the present invention includes but not limited to: glove that use in food service industry, banking or the gardening field or rubber finger-type thing comprise the gym suit of holder and glove etc.
When coating of the present invention was discussed, except as otherwise noted, percentage ratio was mass percent.And except as otherwise noted, these percentage ratios are meant the coating liquid that is used for coated article, rather than the dried amount of coating liquid.
The percentage by weight of term " low concentration " expression zinc salt (comprising zinc ion and bound fraction thereof) is less than 2 weight %, for example about 0.05-2 weight %, or about 0.1-2 weight %, or about 0.1-0.5 weight %, or about 0.5-1.5 weight %, or about 0.2-0.5 weight %, or about 0.1-1 weight %, or about 0.5-2 weight %.Preferably, the total amount (weight of all water-soluble zinc salts of combination) of the water-soluble zinc salt that exists in the present composition (preparation and coating) is about 0.1-0.5 weight %, or less than 0.3 weight %, or be less than or equal to 0.2 weight %.
" water solublity " zinc salt is illustrated in 25 ℃ of molar solubilities in water and is at least 0.1 mol, preferably at least 0.17 mol.The water-soluble zinc salt that uses in these preparations comprises (25 ℃ of zinc acetates, molar solubility 1.64 mol in the water), zinc butyrate (molar solubility 0.4 mol in water), zinc gluconate (molar solubility 0.28 mol in water), glyceric acid zinc (water solublity is medium), glycolic zinc (water solublity is medium), zinc formate (20 ℃, molar solubility 0.33 mol in water), zinc lactate (molar solubility 0.17 mol in water), selenium picolinate (water solublity is medium), zinc propionate (molar solubility 1.51 mol in water), zinc salicylate (low aqueous solubility), zinc tartrate (water solublity is medium) and Zinc Undecylenate (water solublity is medium).In preferred non-limiting embodiment, the invention provides the prescription of the article coatings that comprises two or more water-soluble zinc salts, molar solubility is about the 0.17-1.64 mol in the water of every kind of zinc salt, and wherein the total weight percent of all water-soluble zinc salts is about 0.1-0.5 weight % or is less than or equal to about 0.3 weight %.
As used herein, term " water-insoluble " zinc salt is represented the chemical compound of 25 ℃ of following water solublity less than 0.1 mol.The non-limitative example of water-insoluble zinc salt comprises: zinc oxide, zinc stearate, zinc citrate, zinc phosphate, zinc carbonate and Firebrake ZB.In concrete non-limiting embodiment, the concentration that the water-insoluble zinc salt exists is about 0.05-0.5 weight % or about 0.1-1 weight %.
In other concrete non-limiting embodiment, all zinc salts comprise that the total amount of water solublity and water-insoluble zinc salt is about 0.1-1.5 weight %, or about 0.1-1 weight %.
Term " prevents " or " reduction " stimulates expression to compare with the control tissue that contacts the barrier that is coated with the same preparation that lacks zinc salt, objective or subjective irritation sign reduction at least 50% in the tissue of contact with the medical article of the preparation coating of the present invention of two or more water solublity organic zinc salts that comprise low concentration more preferably reduces more than 90%.Stimulation in this linguistic context can show as rubescent or other change color, inflammation or swelling, allergy, burns, pruritus or other pain stimulation, chap, wrinkling, erythra, urticaria or those of ordinary skills are known changes with stimulating other relevant macroscopic view or microcosmic.
Preparation of the present invention can be used as coating and is applied over and has the goods with upper surface, so that apply at least one product surface (whole surface or its part).As concrete non-limiting embodiment, coating of the present invention can be applied to the inner surface of glove or condom, or is applied to the outer surface of glove or condom, or is applied to the surfaces externally and internally of glove or condom simultaneously.Can use different coating on each surface.Coating can be applied on the part on surface, such as but not limited to, be applied on the inner surface of one or more finger tips on the glove.
A plurality of embodiment of the present invention can comprise softening agent; such as but not limited to: PEG20 Semen Armeniacae Amarum glyceride; Probutyl DB-10; methyl glucosamine polyoxypropylene (20) ether (Glucam P-20); methyl glucosamine poly(ethylene oxide) (10) ether (Glucam E-10); methyl glucosamine polyoxypropylene (10) ether (GlucamP-10); methyl glucosamine poly(ethylene oxide) (20) ether (Glucam E-20); methyl glucosamine polyoxypropylene (20) ether (Glucam P-20) distearate; (Procetyl 10, Croda) for cetyl polyoxypropylene (10) ether; because of overstating (Incroquat) in the Crow; glycerol; propylene glycol; the acetic acid cetyl ester; and Acetylated lanolin alcohols.; margaron; myristicin (myristyril ether); hydroxylating breast glyceride (hydroxylated milkglycerides); polyquaternary ammonium salt (polyquaternium) chemical compound; chlorination dimethyldiallylammonium and acrylic acid copolymer; the dipropylene glycol methyl ether; polypropylene glycol ether and silicon polymer.Other suitable softening agent comprises the alkyl softening agent, for example vaseline or mineral oil; Fat ester group softening agent, the for example methyl of fatty acid, isopropyl and butyl ester, for example isopropyl palmitate, isopropyl myristate, isostearic acid isopropyl ester, the different stearyl ester of iso stearate, Dermol DIPS and two n-nonanoic acid propylene esters, different n-nonanoic acid 2-ethyl hexyl ester (2-ethylhexyl isononoate), stearic acid 2-ethyl hexyl ester, lactic acid C 12-C 16Aliphatic alcohol ester such as cetyl lactate and lactic acid ten diester, isopropyl lanolate, salicylic acid 2-ethyl hexyl ester, myristic acid cetyl ester, myristic acid grease, stearic acid grease, Cetiol, lauric acid hexyl ester and lauric acid dissident ester.Other softening agent comprises lanoline, olive oil, cocoa butter and Adeps Bovis seu Bubali resin (shea butter).
The invention provides and in preparation and coating, mix one or more emollient solvent.The preferred emollient solvent of the present invention comprise hot oxygen glycerol (octoxyglycerin,
Figure A200680055496D00071
), pentanediol, 1,2 hexanediol and XINYI glycol (caprylyl glycol), such as but not limited to concentration for being no more than 5% or be no more than 3%, for example about 0.05-5%, or about 0.1-3%.
A plurality of embodiment of the present invention can comprise stabilizing agent, such as but not limited to: antioxidant (concentration can be 0.2-1%), such as but not limited to vitamin C (ascorbic acid) or vitamin E (tocopherol).
Be surprised to find that stabilizing agent can eliminate the turbidity of preparation, obtain clarifying product, give application surface and feel with light.
A plurality of embodiment of the present invention can comprise thickening agent, such as but not limited to (preferred concentration 0.6-2%): stearyl alcohol, cationic hydroxyethyl cellulose (U Care JR30; Amerchol), (Kytamer), behenyl alcohol, zinc stearate, Crodamol STS (Croda) or emulsifing wax are such as but not limited to overstating because of the Crow and Bora wax (Polawax) for hydroxypropyl emthylcellulose, hydroxypropyl cellulose (Klucel), Polyox N-60K, chitosan 2-pyrrolidone-5-carboxylic acid ester.Other thickening agent and/or gellant that is fit to be included in preparation described herein or the ointment for example comprises, acrylic acid addition polymers, resin as
Figure A200680055496D00072
ETD TM2020, guar gum, arabic gum, acrylate/stearyl poly(ethylene oxide) (20) ether metacrylic acid ester copolymer, agar, algin, alginic acid, the ammonium acrylate copolymer, ammonium alginate, ammonium chloride, ammonium sulfate, amylopectin, attapulgite, bentonite, C9-15 alcohol, calcium acetate, calcium alginate, calcium carrageenan, calcium chloride, capryl alcohol, carbomer 910, carbomer 934, carbomer 934 P, Acritamer 940, Carbopol 941, carboxymethyl hydroxyethyl cellulose, Carboxymethyl hydroxypropyl guar, carrageenin, cellulose, cellulose gum, spermol (cetearyl alcohol), hexadecanol, corn starch, (crodomol) rubs more in the Crow, pentaerythritol stearate (crothix), Dammar, dextrin, bigeminy aniline (dibenzlidine) Sorbitol, two (hydrogenated tallow acyl) ethylenediamine, two oleoyl ethylenediamines (olamide), ethylenedistearamide, gelatin, guar gum, guar gum hydroxypropyl-trimethyl ammonium chloride (guarhydroxylpropyl trimonium chloride), Strese Hofmann's hectorite., hyaluronic acid, hydrated SiO 2, hydroxy butyl methyl cellulose, hydroxyethyl-cellulose, hydroxyethyl ethylcellulose, ethoxy stearmide-MIPA, different hexadecanol, isooctadecanol, karaya, kelp ashes, lauryl alcohol, carob gum, aluminium-magnesium silicate, magnesium silicate, magnesium trisilicate, methoxyl group PEG-22/ dodecyl diol copolymer, methylcellulose, microcrystalline Cellulose, montorillonite clay, myristyl alcohol, oatmeal, oleyl alcohol, palm kernel alcohol, pectin, PEG-2M, PEG-5M, polyacrylic acid, polyvinyl alcohol, potassium alginate, polyacrylic acid potassium aluminum, carrageenin potassium, potassium chloride, potassium sulfate, potato starch, propylene glycol, propylene glycol alginate, sodium acrylate/ethenol copolymer, Sensor Chip CM 5 sodium, carrageenin sodium, cellulose sodium sulfate, sodium chloride, sodium polymethacrylate, sodium aluminosilicate, sodium sulfate, stearic alkane (stearalkonium) bentonite, stearic alkane Strese Hofmann's hectorite., stearyl alcohol, tallow alcohol, the TEA-hydrochlorate, Tragacanth, tridecanol, the trometamol aluminium-magnesium silicate, wheat flour, wheaten starch, xanthan gum, abienol, propylene linoleic acid behenic acid aluminum, aluminium octoate, dilinoleic acid aluminum, aluminum salt such as distearate and isostearic acid aluminum, Cera Flava Shan Yu amide, butadiene/acrylonitrile copolymer, C29-70 acid behenic acid calcium, calcium stearate, candelilla wax, Brazil wax, ceresine (ceresin), cholesterol, the hydroxy stearic acid cholesteryl ester, coconut alcohol, Resin copal, diglycerol stearic acid malate (diglyceryl stearatemalate), the dihydro abienol, dimethyl lauryl amine oleate, dodecanoic acid/spermol/diol copolymer, erucyl amide, ethyl cellulose, glycerol triacetyl hydroxy stearic acid ester, glycerol triacetyl ricinoleate ester Er behenic acid diol ester, two sad diol esters, distearyl acid diol ester, distearyl acid hexanediol ester, hydrogenation C6-14 olefin polymer, castor oil hydrogenated, hydrogenated cottonseed oil, hydrogenated lard, the hydrogenation pilchardine, hydrogenated palm kernel glyceride, hydrogenated palm kernel oil, hydrogenated palm oil, Parleam, oil with hydrogenated soybean, the hydrogenated tallow amide, hydrogenated tallow glyceride, hydrogenated vegetable glyceride, hydrogenated vegetable oil, lacquer tree fat, jojoba wax, lanolin alcohol, Adeps Bovis seu Bubali resin, lauramide, the dehydrogenation Abalyn., hydrogenated rosins acid methyl ester, lambertianic methylate, methyl styrene/vinyl toluene copolymer, microwax, montanic acid wax, montan wax, the myristyl EICOSANOL, the myristyl octadecanol, octadecylene/copolymer-maleic anhydride, octyl dodecanol stearoyl-oxy stearate (Octyldodecyl stearoyl stearate), oleamide, the oleoyl stearic acid, ouricury wax, oxidic polyethylene, ceresine (ozokerite), paraffin, hydrogenated rosins acid pentaerythritol ester, Pentaerythrityl tetraoctanoate, the resin acid pentaerythritol ester, four rosin acid pentaerythritol ester Si behenic acid pentaerythritol esters, four pentaerythritol oleates, pentaerythritol tetrastearate, ophthalmic acid acid anhydride/glycerol/capric acid glycidyl ester copolymer, ophthalmic acid/trimellitic acid/diol copolymer, polybutene, Polybutylene Terephthalate, poly-cinene, polyethylene, polyisobutylene, polyisoprene, polyvinyl butyral resin, the polyvinyl alcohol laurate, two sad propylene glycol esters, two theobromic acid propylene glycol esters, two different n-nonanoic acid propylene glycol esters, two lauric acid propylene glycol esters, two n-nonanoic acid propylene glycol esters, the distearyl acid propylene glycol ester, two-undecanoic acid propylene glycol ester, PVP/ icosa alkene copolymer, PVP/ hexadecylene copolymer, rice bran wax, stearic alkane bentonite, stearic alkane Strese Hofmann's hectorite., stearmide, stearmide DEA-distearate, stearmide DIBA-stearate, stearmide MEA-stearate, stearone, the stearyl erucyl amide, stearic acid octadecanol ester, stearyl alcohol stearoyl-oxy stearate, synthetic bees wax, synthetic wax, trihydroxy stearin (trihydroxystearin), three different essences in the ninth of the ten Heavenly Stems (triisononanoin), three glyceryl isostearates (triisostearin), three isooctadecanol trimerized linoleic acid esters, trilaurin (trilaurin), three linoleic acids, Trilinoleyl glyceride (trilinolein), myristin (trimyristin), glycerol trioleate (triolein), tripalmitin (tripalmitin), glyceryl tristearate (tristearin), Dodecanoic acid, zinc salt, Grillocin P 176, zinc neodecanoate, resin acid zinc and their mixture.
Embodiments of the present invention can comprise phenoxyethanol (0.3-1.0%) as solubilizing agent.
A plurality of embodiment of the present invention can comprise wetting agent, such as but not limited to: glycerol, pantothenylol, methyl glucosamine polyoxypropylene (20) ether, 1-2-propylene glycol, dipropylene glycol, Polyethylene Glycol, 1,3 butylene glycol or 1,2,6-hexanetriol.The concentration of wetting agent is about 0.1-5%, or about 0.1-0.5%.
In non-limiting embodiment, coating of the present invention comprises one or more antimicrobials or antiseptic, and preferred total concentration is 0.05-5 weight % or 0.05-2 weight % or 0.1-2 weight %.Preferred antimicrobial and/or examples of preservatives include but not limited to: chlorhexidine gluconate (CHG), benzalkonium chloride (BZK) or iodo propinyl butyl carbamate (IPBC; Lattice mocha (Germall plus)).Other example of antimicrobial includes but not limited to: iodophors, iodine, benzoic acid, dihydrokainic acid, propanoic acid, sorbic acid, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, cetab, quaternary ammonium compound, include but not limited to benzethonium chloride (BZT), dequalinium chloride, biguanide such as chlorhexidine (comprising free alkali and salt (as follows)), PHMB (poly hexamethylene biguanide), chlorocresol, chloroxylenol (chlorxylenol), benzyl alcohol, bronopol, chlorobutanol, ethanol, phenoxyethanol, phenethanol, 2, the 4-dichlorbenzyl alcohol, thimerosal, clindamycin, erythromycin, benzoyl peroxide, mupirocin, bacitracin, polymyxin B, neomycin, triclosan, to chloro-m-xylene, phosphine formic acid, miconazole, fluconazol, Itraconazole, ketoconazole and pharmaceutically acceptable salt thereof.
Concrete non-limiting embodiment of the present invention does not comprise quaternary ammonium compound basically, such as but not limited to benzalkonium chloride, benzethonium chloride (BZT) and dequalinium chloride.
The pharmaceutically acceptable chlorhexidine salt that can be used as antimicrobial according to the present invention includes but not limited to: the Palmic acid chlorhexidine, diaminobenzene phosphonic acids (diphosphanilate) chlorhexidine, didextrose acid chlorhexidine, the oxalic acid chlorhexidine, two hydrochloric acid chlorhexidines, the dichloride chlorhexidine, dihydro iodate chlorhexidine, two perchloric acid chlorhexidines, the dinitric acid chlorhexidine, the sulphuric acid chlorhexidine, the sulfurous acid chlorhexidine, the thiosulfuric acid chlorhexidine, oneself is fixed for two acid p chloromethylbenzoic acids, the difluorophosphoric acid chlorhexidine, the dioctyl phthalate chlorhexidine, the dipropionic acid chlorhexidine, two iodo butanoic acid chlorhexidines, two positive valeric acid chlorhexidines, two caproic acid chlorhexidines, the malonic acid chlorhexidine, the succinic acid chlorhexidine, the malic acid chlorhexidine, the tartaric acid chlorhexidine, two monoethanols acid chlorhexidine, single diethyl alkyd chlorhexidine, the lactyl-lactic acid chlorhexidine, two-alpha-hydroxybutyric dehydrogenase chlorhexidine, two glucoheptonic acid chlorhexidines, two different thiosulfuric acid chlorhexidines, the dibenzoic acid chlorhexidine, two cinnamic acid chlorhexidines, two mandelic acid chlorhexidines, two M-phthalic acid chlorhexidines, two-2 hydroxy naphthalene acid chlorhexidine and pamoic acid chlorhexidine.Chlorhexidine free base is the example of another antimicrobial.
These and other example of spendable antimicrobial is referring to " pharmacological basis of therapeutic agent " (The Pharmacological Basis of Therapeutics) (GoodmanGilman A of Goodman and Gilman among the present invention, Rail TW, Nies AS, Taylor P compiles (Pergamon Press; Elmsford, N.Y.:1990)), its content is included in this by reference.
A plurality of embodiment of the present invention can comprise the carboxyl that neutralization reagent neutralizes and exists in one or more other compositions, for example carboxyl in the thickening agent.Suitable neutralization reagent comprises diisopropylamine and triethanolamine.
A plurality of embodiment of the present invention can comprise surfactant.Surfactant can be anion surfactant, cationic surfactant, amphoteric surfactant or non-ionic surface active agent.The example of non-ionic surface active agent comprises: polyethoxylate, aliphatic alcohol are (for example, cetyl poly(ethylene oxide) (20) the ether poly(ethylene oxide) cetyl ether of about 20 ethylene oxide units (have average) and from ICI Americas, Inc. other of (Wilmington, DE)) " Brij (BRIJ) "
Figure A200680055496D0010142427QIETU
Non-ionic surface active agent, Folium Cocoe amido propyl betaine, alkyl phenol, the fatty acid ester of Sorbitol, sorbitan or poly(ethylene oxide) sorbitan.Suitable anion surfactant comprises ammonium lauryl sulfate and lauryl ether sulfosuccinate.Preferred surfactants comprises that the lauroyl ethylenediamine triacetic acid sodium salt of the about 0.5-2.0% of concentration, about 2.0% general sieve stream Buddhist nun (Pluronic) F87, MasilSF-19 (BASF) and INCA buy the base of a fruit (incromide).The concentration that surfactant is suitable is about 0.05%-2%.
The water that uses in the preparation described herein preferably has the deionized water of neutral pH.Spendable alcohol includes but not limited to ethanol and isopropyl alcohol according to the present invention.
Non-limiting embodiment of the present invention can comprise silicone powder, such as but not limited to DOW CORNING 9701 face powders (Dow Corning 9701 Cosmetic Powder).In concrete non-limiting embodiment, the powder consumption is about 0.1-5%, or about 0.2-1%.A plurality of embodiment of the present invention can comprise extra additive, include but not limited to: silicone oil (for example simethicone or cyclomethicone); Silicone emulsion; Dyestuff; Aromatic; The pH regulator agent, comprise alkaline pH regulator such as ammonia, single-, two-and trialkylamine, single-, two-and three alkanolamines, alkali metal and alkaline earth metal hydroxide (for example, ammonia, sodium hydroxide, potassium hydroxide, Lithium hydrate, monoethanolamine, triethylamine, 2-aminopropane., diethanolamine and triethanolamine); Acidic ph modifier, for example mineral acid and polycarboxylic acid (for example, hydrochloric acid, nitric acid, phosphoric acid, sulphuric acid, citric acid, glycolic and lactic acid); Vitamin, for example vitamin A, vitamin E and vitamin C; Polyamino acid and salt, for example ethylenediaminetetraacetic acid (EDTA); Antiseptic, for example Ge Mojia and DMDM Hydantoin.
A plurality of embodiment of the invention can comprise quintessence oil (" EO "), quintessence oil is the volatile oil available from plant or animal origin, comprise one or more activating agents (being also referred to as separated component or " IC " here), these activating agents include but not limited to monoterpene and sesquiterpene hydro carbons, alcohol, ester, ether, aldehyde, ketone or oxide.The example of EO includes but not limited to: almond oil, Cananga odorata oil, orange blossom oil, sandalwood oil, blue red oil, Oleum menthae, Oleum lavandula angustifolia, Jasmin oil, citronella oil bourbon, oleum menthae viridis, Oleum Caryophylli, Herba Cymbopogonis oil, Cedar wood oil, balsam tree oil and tangerine oil.Perhaps, the present invention uses the activating agent of finding (IC) in quintessence oil, such as but not limited to: 1-citronellol, jasminal, LYRAL (lyral), geraniol, farnesol, hydroxycitronellal, isoeugenol, eugenol, Eucalyptus oil and eucalyptol, Fructus Citri Limoniae oil, linalool and citral.Except being used as aromatic or correctives, these chemical compounds also can be used as antimicrobial in the present invention.The concentration of EO or IC is about 0.3-1 weight % or about 0.1-0.5 weight % or 0.5-2 weight % (all are weight percent values).
Ambient temperature is defined as 20-35 ℃ here.Room temperature is defined as 20-25 ℃ here.
The invention provides and use above-mentioned composition to prevent the method that epithelial tissue (for example mucosal tissue or skin) stimulates, this method comprise the compositions with effective dose be applied to will with product surface or coating that skin or mucosal tissue contact in.The stimulation that protective effect can resist includes but not limited to: the stimulation that physics, chemistry, machinery or biological stimuli cause.The object lesson of above-mentioned stimulus object includes but not limited to: the mode of removal hair (for example, depilatory, wax and razor), hair (for example speeds slow agent, sodium hydroxide, calcium hydroxide, thioglycolate salt), Antiperspirant (for example, aluminum chlorhydrate and other aluminum salt), the treating skin disease agent (for example, alpha hydroxy acid (AHA), especially glycolic and trichloroacetic acid), keratolysis skin irritation disease (for example, psoriasis, the dandruff etc.), infectiousness skin stimuli (for example antibacterial and fungus) and as the medicament of therapeutic purposes.Need protection in order to avoid the epithelial surface that is upset can be corium or mucosa, comprise vagina, anal orifice and rectal intestine, oral cavity or nasal cavity.
The example of the infectious substance that protective effect can resist includes but not limited to: the infectious substance relevant with sexually transmitted disease (STD); comprise human immunodeficiency virus (HIV); human papillomavirus (HPV); herpes simplex virus (HSV); chlamydia trachomatis; gonococcus belongs to; the infectious substance that may run in trichomonal vaginitis and Candida albicans and the health care environments; include but not limited to aurococcus; Pseudomonas aeruginosa; streptococcus pneumoniae; escherichia coli; Salmonella typhimurium; enterococcus and meningitis naphthalene plucked instrument Salmonella; HIV; varicella zoster virus and hepatitis (for example, first; second and hepatitis C) virus.
In some optional non-limiting example, preparation of the present invention and/or coating lack the antimicrobial that is selected from down group: iodophors, iodine, benzoic acid, dihydrokainic acid, propanoic acid, sorbic acid, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, cetab, quaternary ammonium compound, include but not limited to benzalkonium chloride, dequalinium chloride, biguanide, chlorhexidine (comprising free alkali and salt (as follows)) for example, chlorocresol, chloroxylenol (chlorxylenol), benzyl alcohol, bronopol, chlorobutanol, ethanol, phenoxyethanol, phenethanol, 2, the 4-dichlorbenzyl alcohol, thimerosal, clindamycin, erythromycin, benzoyl peroxide, mupirocin, bacitracin, polymyxin B, neomycin, triclosan, to chloro-m-xylene, phosphine formic acid, miconazole, fluconazol, Itraconazole, ketoconazole and pharmaceutically acceptable salt thereof.
In other embodiment, the invention provides and can be applicable to the zinc serosity of latex product (for example condom or glove) to reduce or to prevent to stimulate.The zinc serosity can comprise, such as but not limited to, at least two kinds of water-soluble zinc salts (as mentioned above) of concentration 0.5-2%, one or more water-insoluble zinc salts (as mentioned above) of optional concentration 0.1-1% and the pantothenylol of concentration 0.1-4%.This serosity can with such as the liquid of silicone oil with the mixed of 1:5 to 1:10, be applied to then will with the product surface of contact skin.In a concrete non-limiting example, the invention provides the Emulsion that can be used for application glove (for example latex glove) inner surface.
In one group of concrete non-limiting example, the invention provides application of paint or be applied to coating on the goods, it comprises: two kinds of water-soluble zinc salts, every kind of concentration is 0.1-1 weight %; The pantothenic acid derivative of the about 0.05-0.5 weight of concentration %, for example pantothenylol; And the aforesaid antimicrobial of the about 1-5 weight of concentration % (for example, biguanide such as chlorhexidine).This coating solution can also comprise the silicone emulsion of the about 70-95 weight of concentration %.In some non-limiting example, described coating also comprises the third water-soluble zinc salt of concentration 0.1-1 weight %.In some non-limiting example, in the coating that randomly comprises the third water-soluble zinc salt, the merging amount of all water-soluble zinc salts is about 0.1-2 weight %.In some non-limiting examples, described coating comprises the aforesaid silicone powder of the about 0.2-1% of concentration.
In concrete non-limiting embodiment, the invention provides a kind of coating preparation, it comprises:
(i) chlorhexidine gluconate of the about 2-4 weight of concentration %;
The (ii) pantothenylol of the about 0.3-1 weight of concentration %;
The (ii) zinc acetate of the about 0.1-0.5 weight of concentration %;
The (ii) zinc lactate of the about 0.5-1.5 weight of concentration %;
The (ii) quaternary ammonium compound of the about 0.05-0.2 weight of concentration %; With
(the vi) silicone emulsion of the about 1-5 weight of concentration %, wherein, described preparation does not comprise water-fast zinc salt, randomly also comprises about 0.5-2 weight % farnesol, the hot oxygen glycerol of about 0.5-3 weight %, and/or about 0.1-0.5 weight % silicone powder.
In other nonrestrictive embodiments, the invention provides a kind of coating preparation, it comprises:
(i) chlorhexidine gluconate of the about 2-4 weight of concentration %;
The (ii) pantothenylol of the about 0.3-1 weight of concentration %;
The (iii) zinc acetate of the about 0.1-0.5 weight of concentration %;
The (iv) zinc lactate of the about 0.5-1.5 weight of concentration %;
(the v) zinc oxide of the about 0.1-1.0 weight of concentration %;
(the vi) silicone emulsion of the about 1-5 weight of concentration %, wherein said preparation does not comprise quaternary ammonium compound, randomly also comprises the farnesol of about 0.5-2 weight %, the hot oxygen glycerol of about 0.5-3 weight %, and/or the silicone powder of about 0.1-0.5 weight %.
In other nonrestrictive embodiment, the invention provides a kind of coating preparation, it comprises:
(i) chlorhexidine gluconate of the about 2-4 weight of concentration %;
The (ii) pantothenylol of the about 0.3-1 weight of concentration %;
The (iii) zinc acetate of the about 0.1-0.5 weight of concentration %;
The (iv) zinc lactate of the about 0.5-1.5 weight of concentration %;
(the v) quaternary ammonium compound of the about 0.05-0.2 weight of concentration %;
(the vi) silicone emulsion of the about 1-5 weight of concentration %;
(the farnesol of vii) about 0.5-2 weight %;
(the hot oxygen glycerol of viii) about 0.5-3 weight %; With
(ix) silicone powder of about 0.1-0.5 weight %.In nonrestrictive embodiment, the invention provides a kind of goods, medical article especially, it prepares by the following method: apply uncoated product surface with described coating preparation above.Apply this based article the zest of these goods when contact skin or mucosa reduced, goods can more effectively be prevented the spread of infectious diseases.
Table 1 provides each the component concentrations scope that comprises in the preparation of non-limiting example of the present invention.
Table 1
Composition Chemical name
Chlorhexidine gluconate 20% solution Solubility or insoluble Guanoctine or free alkali 0.05％-10.0％
Water If desired, QS to 100%
The D pantothenylol D and/or L pantothenylol 0％-3.0％
Zinc acetate, 100% 0％-2.0％
Lactate, 100% 0％-5.0％
Ucare?JR30M，100％ Polyquaternary ammonium salt 10 0％-2.0％
Benzethonium chloride, 100% Alkylaryl-dimethyl chlorination quaternary ammonium (quaternaryalkylaryl-dimethylammonium chloride) chemical compound 0％-3.5％
Zinc gluconate, 100% 0.01％-5.0％
Phenoxyethanol, 100% 0％-3.0％
Teric?N-100，20％ The ethoxylated nonylphenol of EO 3-150 0％-10.0％
Detex?A50，50％ 0％-3.0％
Silicone DOW CORNING 939,35% Amino-functional type siloxanes (Amenofunctional Siloxane) 0％-7.0％
Farnesol, 100% Type sesquiterpene 0％-5.0％
1,2-ethohexadiol, 98+% Containing or not double bond containing aliphatic and/or aromatic series and/or cyclic diols of 2-20 carbon 0％-10.0％
Hydrolite?5 Containing or not double bond containing aliphatic and/or aromatic series and/or cyclic diols of 2-20 carbon 0％-10.0％
Sensiva Hot oxygen glycerol (Octoxyglycerin) 0％-5.0％
Silicone-9701 Amorphous fumed silica 0％-3.0％
Table 2 provides each the component concentrations scope that comprises in the preparation of non-limiting example of the present invention, do not comprise insoluble zinc salt.
Table 2
Composition Weight % (scope)
Phase 1
Chlorhexidine gluconate 2-4
Deionized water 40-60
The D-L pantothenylol 0.3-1.0
Zinc acetate 0.1-0.5
Zinc lactate 0.5-1.5
Ucare?JR-30M 0.1-0.3
Benzethonium chloride 0-0.2
Zinc gluconate 0.2-0.5
Phenoxyethanol 0.5-1.0
Phase 2
Deionized water 20-30
Silicone-DOW CORNING 939 Emulsions 1.0-5.0
Farnesol 0.5-2.0
1, the 2-ethohexadiol 1.0-4.0
Sensiva?SC-50 0.5-3.0
The nonrestrictive method according to the present invention at first prepares two kinds of solution (mutually 1 with mutually 2), they is mixed prepare the coating preparation then.
Table 3 provides each the component concentrations scope that comprises in the preparation of non-limiting example of the present invention, randomly comprises insoluble zinc salt.
Table 3
Composition Weight % (scope)
Phase 1
Chlorhexidine gluconate 2-4
Deionized water 40-60
The D-L pantothenylol 0.3-1.0
Zinc acetate 0.1-0.5
Zinc lactate 0.5-1.5
Ucare?JR-30M 0.1-0.3
Benzethonium chloride 0-0.2
Zinc gluconate 0.2-0.5
Zinc oxide 0-1.0
Phenoxyethanol 0.5-1.0
Phase 2
Deionized water 20-30
Silicone-DOW CORNING 939 Emulsions 1.0-5.0
Farnesol 0.5-2.0
1, the 2-ethohexadiol 1.0-4.0
Sensiva?SC-50 0.5-3.0
The nonrestrictive method according to the present invention at first prepares two kinds of solution (mutually 1 with mutually 2), they is mixed prepare the coating preparation then.
Concrete non-limiting embodiment of the present invention is the preparation shown in the table 4.
Table 4
Composition Weight %
Phase 1
Chlorhexidine gluconate 3.00
Deionized water 53.90
D ' pantothenylol 0.36
Zinc acetate 0.30
Zinc lactate 1.00
Ucare?JR-30M 0.10
Benzethonium chloride 0.20
Zinc gluconate 0.30
Phenoxyethanol 0.55
Subtotal: 59.71
Phase 2
Deionized water 27.36
TericN-100 1.90
Cetrimonium chloride 0.03
Silicone-DOW CORNING 939 Emulsions 2.50
Farnesol 1.00
1, the 2-ethohexadiol 3.25
Pentanediol (Pentylene Glycol) 3.00
Sensiva?SC-50 1.00
Silicone-DOW CORNING 9701 face powders 0.25
Subtotal: 40.29
Amount to: 100.00
This paper has quoted various publications, and their content is whole with reference to being included in this with it.

Claims (18)

1. one kind applies preparation, and it comprises:
(i) chlorhexidine gluconate of the about 2-4 weight of concentration %;
The (ii) pantothenylol of the about 0.3-1 weight of concentration %;
The (iii) zinc acetate of the about 0.1-0.5 weight of concentration %;
The (iv) zinc lactate of the about 0.5-1.5 weight of concentration %;
(the v) quaternary ammonium compound of the about 0.05-0.2 weight of concentration %;
(the vi) silicone emulsion of the about 1-5 weight of concentration %, wherein said preparation does not comprise water-fast zinc salt.
2. coating preparation as claimed in claim 1 is characterized in that, described preparation also comprises the farnesol of about 0.5-2 weight %.
3. coating preparation as claimed in claim 1 is characterized in that, described preparation also comprises the hot oxygen glycerol of about 0.5-3 weight %.
4. coating preparation as claimed in claim 1 is characterized in that, described preparation also comprises the silicone powder of about 0.1-0.5 weight %.
5. one kind applies preparation, and it comprises:
(i) chlorhexidine gluconate of the about 2-4 weight of concentration %;
The (ii) pantothenylol of the about 0.3-1 weight of concentration %;
The (iii) zinc acetate of the about 0.1-0.5 weight of concentration %;
The (iv) zinc lactate of the about 0.5-1.5 weight of concentration %;
(the vi) zinc oxide of the about 0.1-1.0 weight of concentration %;
(the vi) silicone emulsion of the about 1-5 weight of concentration %;
Wherein said preparation does not comprise quaternary ammonium compound.
6. coating preparation as claimed in claim 5 is characterized in that, described preparation also comprises the farnesol of about 0.5-2 weight %.
7. coating preparation as claimed in claim 5 is characterized in that, described preparation also comprises the hot oxygen glycerol of about 0.5-3 weight %.
8. coating preparation as claimed in claim 1 is characterized in that, described preparation also comprises the silicone powder of about 0.1-0.5 weight %.
9. one kind applies preparation, and it comprises:
(i) chlorhexidine gluconate of the about 2-4 weight of concentration %;
The (ii) pantothenylol of the about 0.3-1 weight of concentration %;
The (iii) zinc acetate of the about 0.1-0.5 weight of concentration %;
The (iv) zinc lactate of the about 0.5-1.5 weight of concentration %;
(the vi) quaternary ammonium compound of the about 0.05-0.2 weight of concentration %;
(the vi) silicone emulsion of the about 1-5 weight of concentration %;
(the farnesol of vii) about 0.5-2 weight %;
(the hot oxygen glycerol of viii) about 0.5-3 weight %; With
(ix) silicone powder of about 0.1-0.5 weight %.
10. goods, these goods are prepared by the method that coating preparation as claimed in claim 1 is coated to the uncoated surface of goods.
11. goods, these goods are prepared by the method that coating preparation as claimed in claim 2 is coated to the uncoated surface of goods.
12. goods, these goods are prepared by the method that coating preparation as claimed in claim 3 is coated to the uncoated surface of goods.
13. goods, these goods are prepared by the method that coating preparation as claimed in claim 4 is coated to the uncoated surface of goods.
14. goods, these goods are prepared by the method that coating preparation as claimed in claim 5 is coated to the uncoated surface of goods.
15. goods, these goods are prepared by the method that coating preparation as claimed in claim 6 is coated to the uncoated surface of goods.
16. goods, these goods are prepared by the method that coating preparation as claimed in claim 7 is coated to the uncoated surface of goods.
17. goods, these goods are prepared by the method that coating preparation as claimed in claim 8 is coated to the uncoated surface of goods.
18. goods, these goods are prepared by the method that coating preparation as claimed in claim 9 is coated to the uncoated surface of goods.
CNA2006800554966A 2006-06-02 2006-06-02 Compositions containing zinc salts for coating medical articles Pending CN101500556A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA2006800554966A CN101500556A (en) 2006-06-02 2006-06-02 Compositions containing zinc salts for coating medical articles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2006800554966A CN101500556A (en) 2006-06-02 2006-06-02 Compositions containing zinc salts for coating medical articles

Publications (1)

Publication Number Publication Date
CN101500556A true CN101500556A (en) 2009-08-05

Family

ID=40947227

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800554966A Pending CN101500556A (en) 2006-06-02 2006-06-02 Compositions containing zinc salts for coating medical articles

Country Status (1)

Country Link
CN (1) CN101500556A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106577720A (en) * 2016-06-13 2017-04-26 江西草珊瑚消毒用品有限公司 Use method of composite alcohol disinfection liquid and composite quaternary ammonium salt disinfection liquid
CN107280843A (en) * 2017-07-28 2017-10-24 威海洁瑞医用制品有限公司 Stoma chassis with function of odor removal and fabulous adaptability
CN111568804A (en) * 2020-06-23 2020-08-25 广州澳希亚实业有限公司 Pollen-blocking composition and protective product containing same
CN113185870A (en) * 2021-06-03 2021-07-30 泉州超能涂料有限公司 Special wear-resistant odor-free coating for environment-friendly wood floor and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026134A1 (en) * 1994-03-28 1995-10-05 The Trustees Of Columbia University In The City Of New York Composition for inactivating irritants in fluids
WO1998024426A1 (en) * 1996-12-04 1998-06-11 The Trustees Of Columbia University In The City Of New York Zinc-based antiirritant creams
WO2003034994A3 (en) * 2001-10-23 2003-07-17 Univ Columbia Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
WO2003066001A2 (en) * 2002-02-07 2003-08-14 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
WO2005009352A3 (en) * 2003-07-17 2007-11-29 Univ Columbia Antimicrobial compositons containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026134A1 (en) * 1994-03-28 1995-10-05 The Trustees Of Columbia University In The City Of New York Composition for inactivating irritants in fluids
WO1998024426A1 (en) * 1996-12-04 1998-06-11 The Trustees Of Columbia University In The City Of New York Zinc-based antiirritant creams
WO2003034994A3 (en) * 2001-10-23 2003-07-17 Univ Columbia Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
WO2003066001A2 (en) * 2002-02-07 2003-08-14 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
WO2005009352A3 (en) * 2003-07-17 2007-11-29 Univ Columbia Antimicrobial compositons containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106577720A (en) * 2016-06-13 2017-04-26 江西草珊瑚消毒用品有限公司 Use method of composite alcohol disinfection liquid and composite quaternary ammonium salt disinfection liquid
CN107280843A (en) * 2017-07-28 2017-10-24 威海洁瑞医用制品有限公司 Stoma chassis with function of odor removal and fabulous adaptability
CN111568804A (en) * 2020-06-23 2020-08-25 广州澳希亚实业有限公司 Pollen-blocking composition and protective product containing same
CN113185870A (en) * 2021-06-03 2021-07-30 泉州超能涂料有限公司 Special wear-resistant odor-free coating for environment-friendly wood floor and preparation method thereof

Similar Documents

Publication Publication Date Title
CN101163455B (en) Non-irritating compositions containing zinc salts
US7745425B2 (en) Non-irritating compositions containing zinc salts
USRE45435E1 (en) Zinc salt compositions for the prevention of dermal and mucosal irritation
US7435429B2 (en) Zinc salt compositions for the prevention of dermal and mucosal irritation
US8207148B2 (en) Compositions containing zinc salts for coating medical articles
US7879365B2 (en) Zinc salt compositions for the prevention of dermal and mucosal irritation
AU2006344431B2 (en) Compositions containing zinc salts for coating medical articles
CN101500556A (en) Compositions containing zinc salts for coating medical articles
AU2012203660B2 (en) Non-irritating compositions containing zinc salts
RU2399376C1 (en) Compositions containing zinc salts for medical device coating
JP2013099543A (en) Zinc salt composition for coating medical product
KR20090023623A (en) Compositions containing zinc salts for coating medical articles
NZ573447A (en) Compositions containing zinc salts for coating medical articles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090805